Search results for "Tumor marker"

showing 9 items of 49 documents

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

2015

While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in …

Research designPathologyData baseResearch methodologyElectronic medical recordDiseaseReviewProceduresTreatment responseClinical trials; Rare cancers; Research methodology; Clinical Studies as Topic; Humans; Neoplasms; Rare Diseases; Research Design; Hematology; OncologyClinical trialsNeoplasmsReimbursementPriority journaleducation.field_of_studyClinical Studies as TopicClinical studies as topicHematologyRare diseasesEuropeOncologyResearch designResearch DesignClinical decision makingHumanmedicine.medical_specialtyPractice guidelineCase findingPopulationHealth care qualityReviewsCancer researchClinical studyRare DiseasesSDG 3 - Good Health and Well-beingConceptual frameworkmedicineHumansRare cancersTumor markerIntensive care medicineeducationAntineoplastic activityFlexibility (engineering)Surrogate endpointbusiness.industryMethodologyRare cancerStudy designCancer survivalReimbursementClinical trialClinical trials; Rare cancers; Research methodology; Hematology; OncologyPatient informationClinical effectivenessPosition paperNeoplasmbusinessRare disease
researchProduct

The topology of vitronectin: A complementary feature for neuroblastoma risk classification based on computer‐aided detection

2019

Tumors are complex networks of constantly interacting elements: tumor cells, stromal cells, immune and stem cells, blood/lympathic vessels, nerve fibers and extracellular matrix components. These elements can influence their microenvironment through mechanical and physical signals to promote tumor cell growth. To get a better understanding of tumor biology, cooperation between multidisciplinary fields is needed. Diverse mathematic computations and algorithms have been designed to find prognostic targets and enhance diagnostic assessment. In this work, we use computational digital tools to study the topology of vitronectin, a glycoprotein of the extracellular matrix. Vitronectin is linked to…

RiskCancer ResearchStromal celltopologyTumor Markers and SignaturesComputer scienceAngiogenesisTopologyTopologyvitronectinExtracellular matrixComputational biology03 medical and health sciencesNeuroblastoma0302 clinical medicinecomputational biologyNeuroblastNeuroblastomamedicineTumor MicroenvironmentHumansVitronectinCell ProliferationbiologyNeovascularization PathologicComplex networkmedicine.diseasePrognosisExtracellular MatrixOncology030220 oncology & carcinogenesisnetworksbiology.proteinVitronectinStem cellNetworksStromal CellsAlgorithmsInternational Journal of Cancer
researchProduct

Tumor markers in urogynaecological tumors.

2005

Settore MED/06 - Oncologia MedicaSettore BIO/14 - Farmacologiacirculating tumor markers urogynaecological tumors
researchProduct

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

2013

Journal article TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ~480 SNPs at the TERT locus in breast (n = 103,991), ovarian (n = 39,774) and BRCA1 mutation carrier (n = 11,705) cancer cases and controls. Leukocyte telomere measurements were also available for 53,724 participants. Most associations cluster into three independent peaks. The minor allele at the peak 1 SNP rs2736108 associates with longer telomeres (P = 5.8 × 10!-7), lower risks for estrogen receptor (ER)-negative (P = 1.0 × 10!-8) and BRCA1 mutation carrier (P = 1.1 × 10!-5) breast cancers and altered promot…

TelomeraseMessengerCàncer d'ovariEstrogen receptorAetiology screening and detection [ONCOL 5]0302 clinical medicineBreast cancerRisk FactorsAlternative Splicing; Biomarkers Tumor; Breast Neoplasms; Case-Control Studies; Chromatin; DNA Methylation; Female; Gene Expression Profiling; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Luciferases; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polymorphism Single Nucleotide; RNA Messenger; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Telomerase; Telomere; GeneticsGenotypeBUCCAL CELLSLuciferasesTelomeraseOligonucleotide Array Sequence AnalysisOvarian Neoplasms0303 health sciencesTumorTelòmerReverse Transcriptase Polymerase Chain ReactionGENETIC-VARIATIONCOMMON VARIANTSSingle Nucleotidetert-clptm1l locus; genome-wide association; genetic-variation; susceptibility loci; buccal cells; fibroblasts; common variants; carcinoma; reverse-transcriptase htert; metaanalysisTelomereAetiology screening and detection Immune Regulation [ONCOL 5]Chromatin3. Good healthTumor Markers Biological030220 oncology & carcinogenesisFemaleFIBROBLASTSGenotypeSUSCEPTIBILITY LOCICARCINOMASingle-nucleotide polymorphismBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionPolymorphism Single NucleotideArticleCàncer de mama03 medical and health sciencesBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Ovarian cancermedicineGeneticsBiomarkers TumorHumansGenetic Predisposition to DiseaseRNA MessengerPolymorphismAlleleGENOME-WIDE ASSOCIATIONMETAANALYSIS030304 developmental biologyMolecular epidemiology Aetiology screening and detection [NCEBP 1]Breast cancer susceptibilityHereditary cancer and cancer-related syndromes [ONCOL 1]Translational research Genomic disorders and inherited multi-system disorders [ONCOL 3]Gene Expression ProfilingDNA Methylationmedicine.diseaseMolecular biologyTERT-CLPTM1L LOCUSTelomereMinor allele frequencyAlternative SplicingGenetic LociCase-Control StudiesRNABiomarkersREVERSE-TRANSCRIPTASE HTERTGenome-Wide Association StudyNature genetics
researchProduct

Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models

2019

Patient‐derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach …

Tumor Markers and SignaturesCMSShort Reportcolorectal cancerXenograft Model Antitumor AssaysDisease Models AnimalMicecell proliferationxenograft CMStumor subtypeAnimalsHeterograftsHumansxenograftColorectal NeoplasmsPDX
researchProduct

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

2010

Abstract The clinical relevance of angiopoietin-2 (Ang2) in chronic lymphocytic leukemia (CLL) was previously suggested by the association between high Ang2, and shorter progression-free survival reported in small series of patients. Here, we evaluated Ang2 glycoprotein levels in plasma samples collected from a multicentric cohort of CLL patients (n = 316) using an enzyme-linked immunosorbent assay method, and we investigated its prognostic role in relation to time to first treatment (TTFT) and overall survival. Based on a cutoff equal to 2459 pg/mL, we divided our cohort in 2 subsets (high and low Ang2) composing 100 (31.6%) and 216 (68.4%) patients, respectively. High Ang2 was predictive …

glycoproteinMaleTime FactorsZAP-70Chronic lymphocytic leukemiavascular endothelial growth factor aBiochemistryGastroenterologyimmunoglobulin heavy chainsAdult Aged Aged; 80 and over Angiopoietin-2; analysis/blood Blood Chemical Analysis Female Humans Leukemia; Lymphocytic; Chronic; B-Cell; blood/diagnosis/mortality/therapy Male Middle Aged Neoadjuvant Therapy Prognosis Survival Analysis Time Factors Tumor Markers; Biological; bloodBlood plasma80 and overChronicTumor MarkersAged 80 and overLeukemiaHematologyHazard ratioprotein kinaseHematologyanalysis/bloodMiddle Agedchronic b-cell leukemiasPrognosisLymphocyticNeoadjuvant TherapyLeukemiaCohortFemaleAdultmedicine.medical_specialtyImmunologyangiopoietins chronic b-cell leukemias chronic lymphocytic leukemia plasma vascular endothelial growth factor a cd38 enzyme-linked immunosorbent assay glycoprotein immunoglobulin heavy chains protein kinaseNOcd38Angiopoietin-2bloodInternal medicinemedicineBiomarkers Tumorchronic lymphocytic leukemia angiopoietin-2.Humansbeta(2)-microglobulinplasmaSurvival analysisblood/diagnosis/mortality/therapyAgedbusiness.industryB-CellCell BiologyBiologicalmedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisConfidence intervalImmunologychronic lymphocytic leukemiaangiopoietin-2enzyme-linked immunosorbent assaybusinessCLL; angiopoietin-2; beta(2)-microglobulin; ZAP-70; CD38Settore MED/15 - Malattie del SangueangiopoietinsBlood Chemical AnalysisCLLCD38Blood Chemical Analysis; Angiopoietin-2; Humans; Neoadjuvant Therapy; Prognosis; Aged; Aged 80 and over; Leukemia Lymphocytic Chronic B-Cell; Adult; Middle Aged; Tumor Markers Biological; Time Factors; Female; Male; Survival Analysis
researchProduct

Oxidative Stress and DNA Damage in Human Gastric Carcinoma: 8-Oxo-7'8-dihydro-2'-deoxyguanosine (8-oxo-dG) as a Possible Tumor Marker

2013

We characterized the oxidative stress (OS) status by the levels of reduced/oxidized glutathione (GSH/GSSG), malondialdehyde (MDA) and the mutagenic base 8-oxo-7'8-dihydro-2'-deoxyguanosine (8-oxo-dG) in human gastric carcinoma (HGC) samples and compared the results with normal tissue from the same patients. We also analyzed 8-oxo-dG in peripheral mononuclear cells (PMNC) and urine from healthy control subjects and in affected patients in the basal state and one, three, six, nine and twelve months after tumor resection. The levels of DNA repair enzyme mRNA expression (hOGG1, RAD51, MUYTH and MTH1) were determined in tumor specimens and compared with normal mucosa. Tumor specimens e…

lcsh:ChemistryDNA repair enzymeslcsh:Biology (General)lcsh:QD1-999gastric cancertumor markeroxidative stress8-oxo-dGlcsh:QH301-705.5International Journal of Molecular Sciences
researchProduct

Oxidative Stress and DNA Damage in Human Gastric Carcinoma: 8-Oxo-7'8-dihydro-2'-deoxyguanosine (8-oxo-dG) as a Possible Tumor Marker

2013

We characterized the oxidative stress (OS) status by the levels of reduced/oxidized glutathione (GSH/GSSG), malondialdehyde (MDA) and the mutagenic base 8-oxo-7′8-dihydro-2′-deoxyguanosine (8-oxo-dG) in human gastric carcinoma (HGC) samples and compared the results with normal tissue from the same patients. We also analyzed 8-oxo-dG in peripheral mononuclear cells (PMNC) and urine from healthy control subjects and in affected patients in the basal state and one, three, six, nine and twelve months after tumor resection. The levels of DNA repair enzyme mRNA expression (hOGG1, RAD51, MUYTH and MTH1) were determined in tumor specimens and compared with normal mucosa. Tumor specimens exhibited i…

medicine.medical_specialtyPathologyDNA damageDNA repair8-oxo-dGBiologymedicine.disease_causePeripheral blood mononuclear cellArticleCatalysisInorganic Chemistrychemistry.chemical_compoundInternal medicinemedicine8-oxo-dG; DNA repair enzymes; gastric cancer; oxidative stress; tumor markeroxidative stressDeoxyguanosinePhysical and Theoretical ChemistryMolecular BiologySpectroscopyTumor markergastric cancerOrganic ChemistryGeneral MedicineGlutathioneMalondialdehydeComputer Science ApplicationsEndocrinologyDNA repair enzymeschemistrytumor markerOxidative stressInternational Journal of Molecular Sciences; Volume 14; Issue 2; Pages: 3467-3486
researchProduct

Stellenwert des Tumormarkers CA 19–9 in der Differentialdiagnose von Raumforderungen im Pankreaskopf

1996

In 96 patients (ductal pancreatic carcinoma, n = 34; periampullary carcinoma, n = 43; chronic pancreatitis, n = 19) the role of CA 19-9 in the diagnosis of lesions of the head of the pancreas were evaluated. The sensitivity for ductal pancreatic carcinoma was 73.3%, for periampullary carcinoma 48.8%, and specificity was 63.2%. Carcinoembryonic antigen was elevated only in every fifth patient. Even when combining the two tumor markers no increase in sensitivity could be observed. The low specificity of 63%, which decreased to 33% in the case of obstructive jaundice, does not allow adequate preoperative differentiation between cancer patients and those with chronic pancreatitis. In cases of p…

medicine.medical_specialtybiologybusiness.industryCancermedicine.diseaseGastroenterologyCarcinoembryonic antigenmedicine.anatomical_structureInternal medicinemedicinebiology.proteinCarcinomaPancreatitisSurgeryCA19-9Differential diagnosisPancreasbusinessTumor markerDer Chirurg
researchProduct